A small, medicated disc that dissolves between gum and cheek is not automatically a lozenge; it might be a troche, and the difference governs how fast the drug hits your bloodstream, whether it can be swallowed, and even if it will erode dental enamel.
Patients who assume the terms are interchangeable often under-dose, over-pay, or trigger side effects that a quick label check could have prevented.
Physical Design and Dissolution Mechanics
Lozenges are hard, candy-like matrices made by compression or high-temperature molding; they rely on saliva to erode the outer layers and release drug in a gradual, mouth-wide distribution.
Troches are softer, formed at low heat in silicone molds, and engineered to melt uniformly across the mucosal surface so the active ingredient can permeate the buccal lining instead of being diluted in saliva.
Because a lozenge can take 15–30 min to disappear, it is ideal for cough suppression that needs sustained topical anesthesia, whereas a troche that melts in 5–10 min is chosen when rapid systemic uptake is the goal.
Compression Force and Drug Stability
Pharmacists adjust the kilonewton pressure applied during lozenge compression to balance hardness with friability; too little and the lozenge chips in the bottle, too much and the drug may undergo polymorphic conversion that lowers potency.
Troches rarely exceed 2 kN because the base—typically a fusion of gelatin, glycerin, and polyethylene glycol—must remain pliable enough to yield to body temperature yet firm at room temperature.
Absorption Pathways: Oral Cavity vs Gastrointestinal Tract
A lozenge swallowed piecemeal sends at least 60 % of its drug through first-pass hepatic metabolism, trimming bioavailability of compounds like dextromethorphan to barely 15 %.
Troches are designed for buccal or sublingual uptake, bypassing the portal vein and doubling—or tripling—systemic exposure for hormones such as progesterone or testosterone.
Clinicians prescribing compounded bioidentical hormones therefore specify “troche, do not chew or swallow” to preserve that advantage, while a zinc gluconate lozenge is explicitly instructed to “allow to dissolve slowly” so the ion stays in contact with oropharyngeal mucosa.
pH Microenvironment and Ionization
The resting pH of saliva ranges from 6.2 to 7.6, but troche bases often incorporate citrate or bicarbonate buffers that transiently raise mucosal pH to 7.8, suppressing ionization of weak bases like fentanyl and accelerating membrane transit.
Lozenges lack this buffer capacity, so drugs with pKa above 7.4 remain protonated and linger in the mouth longer, extending local action but delaying systemic onset.
Flavor Masking and Sweetener Choices
Hard lozenges tolerate high-temperature flavor oils—peppermint, eucalyptus, anethole—without volatilizing them, giving a sharp, long-lasting taste that also triggers salivation and speeds dissolution.
Troches are processed below 40 °C, so formulators rely on microencapsulated menthol or heat-stable esters that release aroma only when the base softens, preventing the bitter spike common with sublingual films.
Xylitol is preferred in troches because its negative heat of solution provides a cooling sensation that masks the bitterness of steroids like budesonide without raising glycemic load, whereas sucrose-based lozenges remain popular for pediatric cough SKUs despite dental concerns.
Stevia Aftertaste Mitigation
Compounding pharmacies add 0.2 % sodium glycinate to stevia-sweetened troches, binding the steviol glycoside aftertaste that otherwise persists for 20 min and discourages compliance among patients on daily testosterone replacement.
Compounding Variables: Bases, Fillers, and Humectants
A troche base must be hydrophilic enough to release drug yet firm at 25 °C; PEG 1450 alone cracks at the gum line, so 10 % propylene glycol is folded in as a humectant to prevent syneresis during 90-day shelf life.
Lozenge formulators add microcrystalline cellulose to create a porous lattice that channels saliva inward, ensuring the core drug is not trapped inside an impermeable shell.
When pharmacists switch a patient from commercial progesterone capsules to a custom troche, they often reduce the dose by 25 % because the buccal route avoids first-pass metabolism, a titration step rarely needed when converting to lozenge forms that are largely swallowed.
Mold Release Agents
Silicone molds for troches are pre-treated with a 2 % lecithin in ethanol spray to prevent sticking, whereas magnesium stearate is dusted into steel lozenge dies to reduce ejection friction and chipping.
Clinical Use Cases: When to Choose Which
For acute angina, a nitroglycerin troche dissolved under the tongue achieves therapeutic plasma levels in 2 min, a speed impossible with a lozenge that must first erode and then be partly swallowed.
Chronic mucositis from head-and-neck radiation responds better to 25 mg morphine troches used q4h around the clock, because the drug penetrates inflamed mucosa directly, whereas a lidocaine lozenge only numbs the surface for 20 min and cannot control breakthrough pain.
OTC benzocaine lozenges remain the go-to for dentist-free toothache relief because the hard matrix keeps the anesthetic in contact with the gingival cuff longer than a soft troche that would melt away during salivary spikes triggered by dental pain.
Pediatric Compliance Tactics
Children who reject the soft, waxy mouthfeel of nystatin troches will often accept the same drug in a colorful, candy-like lozenge that doubles as a “reward,” but prescribers must warn parents that chewing the lozenge cuts efficacy by half.
Storage and Stability Profiles
Troches stored at 30 °C/70 % RH can sweat glycerin within two weeks, forming a sticky rim that harbors yeast; amber blister packs with a 1 g desiccant keep moisture below 40 % and extend compounding beyond-use date to 90 days.
Lozenges are hydrophobic enough to survive bathroom cabinets, yet flavored versions containing eucalyptus oil can lose 10 % potency every month once the foil sleeve is opened, because the volatile oil sublimes through microscopic pinholes in the foil.
Pharmacists counsel patients to refrigerate progesterone troches but never freeze them—ice crystals rupture the PEG matrix and create dose hot-spots when the troche is later melted in the mouth.
Light Protection
Testosterone troches photodegrade under fluorescent retail lighting, turning the base from translucent to amber within days; amber glass jars with UV-blocking film preserve 98 % label claim at six months.
Cost Drivers and Insurance Reimbursement
Medicare does not cover compounded troches unless the active ingredient appears in the FDA-approved troche guidance list, forcing cash pay; a 30-day progesterone troche supply averages $85 versus $12 for an equivalent swallowed capsule.
Commercial lozenges enjoy OTC status, so insurers rarely reimburse even prescription-grade 2 % lidocaine lozenges, yet the out-of-pocket cost is only $18 for a 24-count box—lower than the compounding fee alone for a troche.
When physicians document “dysphagia precluding oral solids,” some plans downgrade the copay tier for troches, saving patients 50 %, a coding nuance rarely exploited unless the pharmacist submits the claim with the exact ICD-10 dysphagia subcode.
Bulk API Pricing
Compounded troches use micronized estradiol at $2.40 per gram, while lozenge manufacturers buy non-micronized bulk at $0.80 per gram and mill in-house; the particle size difference explains why troches feel smoother yet cost three times more raw material per dose.
Regulatory Classification: FDA vs State Boards
The FDA treats medicated lozenges as solid oral dosage forms subject to full NDA or ANDA pathways, whereas troches fall into the nebulous “compounded drug” category, inspected by state boards under USP <795> rather than federal cGMP.
This gap allows pharmacies to produce batch sizes of 5,000 troches without validation protocols required for a commercial lozenge, but it also means potency variance can reach ±15 % versus the ±5 % enforced for FDA-approved lozenges.
Physicians who prescribe office-use troches for in-office dispensing must hold a separate state wholesale permit, a compliance step irrelevant when handing out sample lozenges repackaged by the manufacturer.
USP <795> Beyond-Use Dating
Water content above 3 % in troches shortens the USP <795> default beyond-use date from 180 days to 90 days, forcing labs to add extra drying cycles that raise production cost but ensure regulatory compliance.
Patient Counseling Checklist
Hand the patient a mirror: place the troque high between cheek and gum, not under the tongue, to minimize salivary washout and reduce swallowing reflex.
Warn that eating, drinking, or even vaping for 15 min after either dosage form can halve absorption; nicotine constricts buccal blood vessels and delays peak levels by 30 min.
Remind denture wearers that a troche can dislodge partial plates—switch to a smaller 1 mL troche mold or prescribe a harder lozenge that can be parked in the vestibule without mechanical interference.
Overdose Red Flags
Patients who chew five lidocaine troches in an hour chasing faster relief can hit serum levels above 5 µg/mL, triggering tinnitus and visual flashes; teach them to track doses on a phone alarm and switch to a single 2 % viscous solution for breakthrough mucositis instead.
Environmental Impact and Disposal
Troches washed down the sink contribute 30 % more pharmaceutical residue to wastewater than lozenges because the soft base dissolves instantly, releasing the entire drug load before reaching treatment plants.
Community take-back programs now accept troches in sealed zipper bags, but they reject lozenges in original blister packs due to the mix of foil and plastic—patients must instead peel out each lozenge and drop the drug only into the collection bin.
Compounding pharmacies can recycle PEG-based troque trimmings into next batches after 72 h quarantine, cutting raw material waste by 8 %, a sustainability edge hard lozenge manufacturers cannot match because rejected tablets are too friable to recompress.
Pet Safety
A 0.3 mg fentanyl troche left on a nightstand can kill a 5 kg terrier within 30 min; advise patients to store troches in screw-cap vials inside a medicine safe, whereas harder lozenges pose lower acute risk because the dog would have to chew through a bitter, dense matrix first.